Smoking Cessation and Nicotine Deaddiction Landscape Report 2024: Therapeutic Assessment of Novel Drug Candidates, Emerging Drugs and the Route to Commercialization
April 12, 2024 10:04 ET
|
Research and Markets
Dublin, April 12, 2024 (GLOBE NEWSWIRE) -- The "Smoking Cessation and Nicotine Deaddiction - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.The global commitment...
Achieve Life Sciences to Present at Life Science Innovation Northwest 2024 Conference
April 11, 2024 08:00 ET
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...
Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
March 20, 2024 08:00 ET
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, March 20, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...
Smoking Cessation and Nicotine De-Addiction Market to Reach USD 27.84 billion by 2031, at a CAGR of 10.2% - Transparency Market Research, Inc.
March 11, 2024 07:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, March 11, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. -The global smoking cessation and nicotine de-addiction market is estimated to flourish at a...
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
March 06, 2024 08:00 ET
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...
Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission
February 29, 2024 08:01 ET
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...
Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement
February 29, 2024 08:00 ET
|
Achieve Life Sciences
$60 million financing upfront with up to an additional $64.2 million tied to exercise of milestone-driven warrants Upfront net proceeds to provide funds to conduct clinical development of...
Nicotine Replacement Therapy Market Insights, Competitive Landscape, and Market Forecast to 2030
February 28, 2024 12:18 ET
|
Research and Markets
Dublin, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The "Nicotine Replacement Therapy - Market Insights, Competitive Landscape, and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's...
Global Substance Abuse Disorder Treatment Research Analysis Report 2024: Public and Private Entities Join Forces to Tackle Substance Abuse Epidemic - Forecasts to 2034
January 31, 2024 09:44 ET
|
Research and Markets
Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Global Substance Abuse Disorder Treatment Market Analysis & Forecast 2024-2034: Market By Treatment; By End-user; and By Region" report has been...
Smoking Cessation Aids Market in the US Undergoes Major Shift Towards Oral NRT Options
January 28, 2024 19:43 ET
|
Research and Markets
Dublin, Jan. 28, 2024 (GLOBE NEWSWIRE) -- The "NRT Smoking Cessation Aids in the US" report has been added to ResearchAndMarkets.com's offering.NRT patches is set to continue to witness steep...